Melanotan I
MT-1 · Afamelanotide · Scenesse
A synthetic alpha-MSH analogue with FDA-orphan drug approval for erythropoietic protoporphyria, producing skin darkening through melanin stimulation.
Half-Life
~40 hours
MW
1646.9 Da
Amino Acids
13 AA
Evidence
High Evidence
Regulatory Status
FDA-approved (Scenesse) for EPP. EMA-approved. Research use for tanning.
In Plain English
A longer-lasting copy of the hormone that tans your skin — designed to cause protective tanning with less UV exposure. FDA-approved (Scenesse) for a rare sun sensitivity disorder. Tans without careless sun exposure.
Overview
Melanotan I (Afamelanotide) is a linear analogue of alpha-MSH with ~1000x longer half-life. It received FDA orphan drug approval as Scenesse for preventing phototoxicity in erythropoietic protoporphyria (EPP). It acts specifically on MC1R to promote eumelanin production.
Common Formats
- Subcutaneous implant (approved pharmaceutical)
- Lyophilized powder (research)
Storage Notes
Refrigerate.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Melanotan I.
Related Compounds
Melanotan II
A cyclic alpha-MSH analogue with potent melanogenic, sexual arousal, and appetite-suppressing effects through broad melanocortin receptor activation.
PT-141
FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, with off-label research in men.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.